Irkutsk Regional Clinical Hospital Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2017
NCT03416062
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Irkutsk Regional Clinical Hospital | Irkutsk regional clinical hospital, winner of the "Mark of the Honor" award

Active Ingredients

Drugs in Phase 3 Trials (5)

inosine (2 trials)

methionine (2 trials)

nicotinamide (2 trials)

ringer's lactate (2 trials)

sodium succinate (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Jaundice (Phase 3)

Jaundice, Obstructive (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 5